Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study

Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pavel M, Wiedenmann B, Seufferlein T, Freiman J, Law L,

Keywords: carcinoid syndrome, telotristat etiprate ,

#394 Efficacy of Telotristat Etiprate in Refractory Carcinoid Syndrome: Results of a Randomized, Placebo-controlled, Multicenter Study

Introduction: Diarrhea associated with carcinoid syndrome (CS) has been attributed to excess serotonin. Telotristat etiprate is an oral serotonin synthesis inhibitor that decreases peripheral serotonin production.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulke M, O'Dorisio T, Phan A, Bergsland E, Freiman J,

Keywords: carcinoid syndrome, telotristat etiprate,

#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome

Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Brown P

Authors: Brown P, Jackson J, Frazier K, Turnage A, Clark E,

Keywords: carcinoid syndrome, TPH inhibitor, 5-HT, tryptophan hydroxylase, clinical trial, serotonin synthesis, serotonin synthesis inhibitor, LX1032, LX1031, Lexicon, IBS, irritable bowel syndrome, SSI,